Conatus Pharma to explore options as liver disease drug fails trial

Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.

The drug developer's shares halved to 48 cents after the bell.